| SHR-2554 / Treeline Biosci |
NCT06122389: SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma |
|
|
| Recruiting | 3 | 130 | RoW | SHR2554; Chidamide analog tablets, SHR2554 analog tablets; Chidamide | Jiangsu HengRui Medicine Co., Ltd. | Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy | 05/26 | 07/26 | | |
| Recruiting | 2 | 319 | RoW | SHR7390, Famitinib, SHR3162, Pyrotinib, Capecitabine, SHR1210, Everolimus, Nab paclitaxel, SHR2554, SHR3680, SHR6390, SHR1701, SERD, AI, VEGFi | Fudan University | Breast Cancer, Metastatic Cancer | 05/23 | 04/25 | | |
NCT06368167: A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma |
|
|
| Not yet recruiting | 2 | 105 | RoW | SHR2554 | Jiangsu HengRui Medicine Co., Ltd. | Follicular Lymphoma | 04/27 | 04/27 | | |
NCT06519526: Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma |
|
|
| Recruiting | 2 | 25 | RoW | SHR-0302, SHR-2554 | Fudan University | Relapsed/Refractory Peripheral T Cell Lymphoma | 02/26 | 08/27 | | |
NCT04407741: Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas |
|
|
| Recruiting | 1/2 | 100 | RoW | SHR2554+SHR1701, SHR1701 | Chinese PLA General Hospital | Solid Tumor, Lymphoma | 12/24 | 12/25 | | |
NCT06173999: A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma |
|
|
| Recruiting | 1/2 | 100 | RoW | SHR2554/CHOP, SHR2554/CHOEP | Jiangsu HengRui Medicine Co., Ltd. | Peripheral T-cell Lymphoma | 12/25 | 12/25 | | |
NCT05559008: A Umbrella Study in R/R PTCL Guided by Molecular Subtypes |
|
|
| Recruiting | 1/2 | 116 | RoW | Azacitidine Injection, Dasatinib, Linperlisib, Tucidinostat, SHR2554, Camrelizumab, Apatinib | Ruijin Hospital | Peripheral T Cell Lymphoma | 03/24 | 01/26 | | |
NCT06568094: A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer |
|
|
| Recruiting | 1/2 | 100 | RoW | HRS-5041 tablets, Abiraterone Acetate tablets（II）, Prednisone Acetate tablets, Docetaxel Injection, HRS-1167 tablets, SHR2554 tablets | Jiangsu HengRui Medicine Co., Ltd. | Prostate Cancer | 09/25 | 12/26 | | |
NCT05896046: SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma |
|
|
| Recruiting | 1/2 | 100 | RoW | SHR2554+ SHR1701, SHR-1701 | Chinese PLA General Hospital | Relapsed or Refractory Hodgkin Lymphoma | 06/25 | 06/26 | | |
NCT05049083: A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects |
|
|
| Active, not recruiting | 1 | 28 | RoW | New Process SHR2554 tablet、Former Process SHR2554 tablet, Former Process SHR2554 tablet、New Process SHR2554 tablet | Jiangsu HengRui Medicine Co., Ltd. | Lymphoma | 01/22 | 04/22 | | |
NCT03603951: A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms |
|
|
| Recruiting | 1 | 231 | RoW | SHR2554, EZH2 Inhibitor | Jiangsu HengRui Medicine Co., Ltd., Peking University Cancer Hospital & Institute | Relapsed or Refractory Mature Lymphoid Neoplasms | 02/23 | 08/23 | | |
NCT05661591: Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects |
|
|
| Completed | 1 | 18 | RoW | SHR2554 Tablets, Fluconazole Capsules | Jiangsu HengRui Medicine Co., Ltd. | Malignant Tumor | 03/23 | 03/23 | | |
NCT06010680: A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers |
|
|
| Completed | 1 | 6 | RoW | [14C]SHR2554 | Jiangsu HengRui Medicine Co., Ltd. | Lymphoma | 11/23 | 11/23 | | |
NCT06093945: Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects |
|
|
| Completed | 1 | 20 | RoW | SHR2554 tablet dosing, Omeprazole tablet dosing | Jiangsu HengRui Medicine Co., Ltd. | Malignant Tumor | 11/23 | 11/23 | | |
ChiCTR2100046099: Clinical trial of an umbrella study of precise treatment of bone and soft tissue sarcoma based on molecular pathways |
|
|
| Recruiting | N/A | 51 | | SHR-1701+Famitinib ;Camrelizumab+SHR-6390 ;SHR-2554 | Affiliated Sixth People's Hospital, Shanghai Jiaotong University; Affiliated Sixth People's Hospital, Shanghai Jiaotong University, self-funded | advanced bone and soft tissue sarcoma | | | | |
